| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002458177 |
| P356 | DOI | 10.1007/S10637-014-0090-9 |
| P698 | PubMed publication ID | 24838627 |
| P5875 | ResearchGate publication ID | 262421979 |
| P50 | author | Juliana Giacomazzi | Q56856368 |
| Osvaldt A | Q57235125 | ||
| Rafael Roesler | Q77616037 | ||
| Patricia Ashton-Prolla | Q92010442 | ||
| Ana Lucia Abujamra | Q37830636 | ||
| Gilberto Schwartsmann | Q37830640 | ||
| Pierre Hainaut | Q50585710 | ||
| Barbara Alemar | Q51720231 | ||
| P2093 | author name string | Guido Lenz | |
| Caroline Brunetto de Farias | |||
| Agnes Hautefeuille | |||
| Patricia Izetti | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53 | Q24300781 | ||
| Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. | Q53530285 | ||
| PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. | Q53867820 | ||
| Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design | Q72732581 | ||
| Pharmacological rescue of mutant p53 conformation and function | Q73316566 | ||
| Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis | Q74449037 | ||
| Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions | Q81618301 | ||
| Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer | Q84959068 | ||
| Pancreatic cancer: pathogenesis, prevention and treatment | Q24670990 | ||
| The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53 | Q24679341 | ||
| Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer | Q27851614 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Pharmacological reactivation of mutant p53: from protein structure to the cancer patient | Q30389604 | ||
| Pancreatic cancer. | Q30490247 | ||
| Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. | Q31041084 | ||
| Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer | Q33591673 | ||
| Targeting p53 for Novel Anticancer Therapy | Q33655329 | ||
| The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. | Q34164259 | ||
| p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma | Q34547830 | ||
| Targeting p53 by small molecules in hematological malignancies | Q34636996 | ||
| p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions | Q34727942 | ||
| Tumor-suppressive pathways in pancreatic carcinoma. | Q34739925 | ||
| A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer | Q36610441 | ||
| PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation | Q36794233 | ||
| Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer | Q37270056 | ||
| PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. | Q39172979 | ||
| Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. | Q39529355 | ||
| PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo | Q39607175 | ||
| PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. | Q39644141 | ||
| PRIMA-1 reactivates mutant p53 by covalent binding to the core domain | Q39857551 | ||
| TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death | Q39902031 | ||
| Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. | Q40502956 | ||
| p53 promotes selection for Fas-mediated apoptotic resistance | Q40857482 | ||
| A point mutation of human p53, which was not detected as a mutation by a yeast functional assay, led to apoptosis but not p21Waf1/Cip1/Sdi1 expression in response to ionizing radiation in a human osteosarcoma cell line, Saos-2. | Q40916454 | ||
| Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax. | Q40928967 | ||
| Pancreatic cancer clinical trials and accrual in the United States | Q42614630 | ||
| Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription | Q44687763 | ||
| P433 | issue | 5 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 783-794 | |
| P577 | publication date | 2014-05-20 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines | |
| P478 | volume | 32 |
| Q35667409 | APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells |
| Q50067502 | Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway |
| Q28077156 | Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness |
| Q28086993 | Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR |
| Q35195881 | Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics |
| Q91923645 | Inhibition of p53 inhibitors: progress, challenges and perspectives |
| Q37176648 | Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy |
| Q58792021 | Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells |
| Q92736081 | Mutant p53 on the Path to Metastasis |
| Q47274927 | PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies |
| Q47371251 | PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation. |
| Q36738640 | PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells |
| Q38810395 | Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor /c-Met/survivin regulated by P53/P21. |
| Q89776551 | Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies |
| Q89157968 | Targeting Transcription Factors for Cancer Treatment |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q26766341 | Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy |
| Q91898958 | Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia |
Search more.